Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · IEX Real-Time Price · USD
37.77
-1.08 (-2.78%)
At close: Apr 23, 2024, 4:00 PM
38.00
+0.23 (0.61%)
After-hours: Apr 23, 2024, 5:30 PM EDT
Company Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.
Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity.
It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Celldex Therapeutics, Inc.
| Country | United States |
| IPO Date | Mar 10, 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 160 |
| CEO | Anthony S. Marucci M.B.A. |
Contact Details
Address: 53 Frontage Road, Suite 220 Hampton, New Jersey 08827 United States | |
| Phone | 908-200-7500 |
| Website | celldex.com |
Stock Details
| Ticker Symbol | CLDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000744218 |
| CUSIP Number | 15117B202 |
| ISIN Number | US15117B2025 |
| Employer ID | 13-3191702 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Anthony S. Marucci M.B.A. | Founder, President, Chief Executive Officer and Director |
| Dr. Tibor Keler | Founder, Chief Scientific Officer and Executive Vice President |
| Sam Martin | Senior Vice President, Chief Financial Officer, Secretary and Treasurer |
| Dr. Margo Heath-Chiozzi M.D. | Senior Vice President of Regulatory Affairs |
| Dr. Diane C. Young M.D. | Senior Vice President and Chief Medical Officer |
| Prof. Joseph P. Schlessinger Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Sarah Cavanaugh | Senior Vice President of Corporate Affairs and Administration |
| Patrick Till | Senior Director of Investor Relations and Corporate Communications |
| Freddy A. Jimenez Esq. | Senior Vice President and General Counsel |
| Dr. Ronald A. Pepin | Chief Business Officer and Senior Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 1, 2024 | 8-K | Current Report |
| Mar 1, 2024 | 424B5 | Filing |
| Feb 28, 2024 | 424B5 | Filing |
| Feb 26, 2024 | 424B5 | Filing |
| Feb 26, 2024 | 10-K | Annual Report |
| Feb 26, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |